Upstream Bio (NASDAQ:UPB) shares rallied 32% Friday following the asthma drug developer’s $255M upsized initial public ...

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

The offering will fund testing of a potential rival to Amgen’s Tezpire and is already the sixth for an immune drug developer ...

Three U.S. healthcare startups priced their initial public offerings (IPO) on Thursday, including Upstream Bio which raised ...

Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease ...

Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion.

Upstream Bio, Inc UPB IPO will take place October, 11 on the NASDAQ exchange under the ticker UPB. The company is offering ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

Three US life-sciences companies hitting the market delivered mostly robust early trading after investors strongly supported ...

Upstream asserts that verekitug could offer advantages over Tezpire, including potentially greater potency and longer dosing intervals. The company is testing intervals of 12 and 24 weeks in its ...

(Reuters) -Upstream Bio, which is developing treatments for some respiratory disorders, said on Thursday it had raised $255 million in its initial public offering in the United States. The drug ...